DISCO Pharmaceuticals, a German biotechnology company, has entered into a strategic research collaboration and option-to-license agreement with AbbVie to discover and develop next-generation AND-gated bispecific therapeutics for solid tumours. The agreement includes $40 million in upfront payments and up to $2.5 billion in potential option, development and other milestone payments, as well as tiered royalties on worldwide net sales.
A strategic collaboration in precision oncology
The agreement combines DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated therapeutic discovery approach with AbbVie’s oncology research and development capabilities.
Under the agreement, DISCO will conduct specified research activities to identify and advance potential therapeutic programmes. Following successful completion of these activities, AbbVie will have the option to exclusively license selected programmes for further development.
The collaboration focuses on solid tumours with high unmet medical need, an area in which improving tumour selectivity remains a major research challenge.
How AND-gated targeting works
DISCO’s DISCOtech® platform systematically maps proteins and their expression patterns on cancer-cell surfaces, collectively known as the surfaceome. The approach is intended to identify combinations of cell-surface targets that can distinguish tumour cells from healthy tissues.
These target pairs provide the basis for AND-gated bispecific therapeutics. Unlike conventional targeting approaches that recognise a single antigen, these molecules are designed to achieve high-avidity binding only when both target antigens are simultaneously engaged on the same cell.
This dual-target recognition mechanism is intended to improve tumour selectivity and reduce on-target, off-tumour toxicity, a significant challenge in the development of treatments for solid tumours. As the collaboration remains at the research and discovery stage, these potential advantages have not yet been established in clinical studies of the resulting programmes.
The company is also developing broader applications of its platform, including antibody-drug conjugates (ADCs) and T-cell engagers. However, the AbbVie announcement specifically identifies AND-gated bispecific therapeutics as the focus of the collaboration.
DISCO’s pipeline and development strategy
Alongside its partnered programmes, DISCO is advancing an internal pipeline of AND-gated therapeutics. The company identifies small cell lung cancer and colorectal cancer among the areas targeted by its lead programmes, which are progressing towards clinical evaluation.
The AbbVie agreement expands DISCO’s network of pharmaceutical partnerships and provides an additional route for the development of its surfaceome-based discovery approach.
The collaboration remains at the research and discovery stage. The companies have not disclosed the number of programmes that may be selected for licensing or a timetable for their potential entry into clinical development.
The agreement’s financial structure links further payments to the selection and development of programmes, allowing AbbVie to pursue selected candidates after DISCO has completed the specified research activities. The maximum announced value is not guaranteed and depends on the achievement of contractual milestones.


